Publications - April 2023

Preprint and peer-reviewed publications from RECOVER’s studies

Effect of Angiotensin-Converting Enzyme Inhibitor and Angiotensin Receptor Blocker Initiation on Organ Support–Free Days in Patients Hospitalized With COVID-19 (Lawler et al., 2023)

In an ongoing adaptive platform trial, the effect of new initiation of an RAS inhibitor (either an ACE inhibitor or an angiotensin receptor blocker [ARB]) on the composite outcome of hospital survival and organ support provision through 21 days was evaluated in patients hospitalized with COVID-19 pneumonia.

Read article